Wimazal, F <br/><br/>
Deferasirox induces regression of iron overload in patients with myelodysplastic syndromes.  [electronic resource] 

 -  European journal of clinical investigation  May 2009 
 - 406-11 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1365-2362 
<br/><br/><label>Standard No.: </label>10.1111/j.1365-2362.2009.02108.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Aged<br/>Benzoates--therapeutic use<br/>Deferasirox<br/>Female<br/>Humans<br/>Iron--analysis<br/>Iron Chelating Agents--therapeutic use<br/>Iron Overload--drug therapy<br/>Male<br/>Middle Aged<br/>Myelodysplastic Syndromes--drug therapy<br/>Treatment Outcome<br/>Triazoles--therapeutic use